This could be easily tested by using clinically approved anticancer drugs dasatinib and bosutinib that inhibit SIK isoforms in addition to their intended targets in a number of cancer cell types, including multiple Burkitt’s lymphoma (BL) cell lines42,55–57, hepatocellular carcinoma58 and prostate carcinoma cells59–61 that have been reported to undergo apoptosis in response to TGFβ. The gene discussed is SIK1; the disease is prostate carcinoma.